R2150. The immunogenicity score makes an implicit assumption that the different MHC-II alleles occur at equivalent frequencies. The usefulness of this measure is accordingly limited for peptides that bind with high affinity to only a limited set of MHC-II alleles that occur at very high or very low frequencies. Taken together, analysis of existing clinical data suggests that the hypotheses illustrated in Figure 1 and Supplementary Figure 1 are plausible. However, these hypotheses remain to be substantiated by carefully designed clinical and experimental studies.
Rapid advances in experimental and computational tools for sequencing make it feasible to more accurately identify individuals at risk of developing alloantibodies to protein therapeutics. Furthermore, in the case of some biologics (e.g., factor VIII for hemophilia A) it may be possible to personalize management of the disease with a 'matched' replacement product 9 . These strategies may offer the benefit of potentially reducing the disproportionate frequency of adverse alloimmune events in vulnerable populations (as has been demonstrably shown for hemophilia A patients of black-African descent 9, 19 ). In practice, the approach may be more relevant to some classes of therapeutic proteins, such as those that provide replacement therapy for proteins that have critical and nonredundant functions. Moreover, it is anticipated that there likely will be hurdles for the development of such personalized approaches to circumvent immunogenicity. For example, all new factor VIII products are first tested in patients that have been previously treated (with >150 exposures to other factor VIII products) and >12 years of age before they are tested in previously untreated patients 20 . The rationale for this testing paradigm is to assess whether a new product is potentially immunogenic to patients who are not susceptible to inhibitor development with comparable products.
Thus, if the regulatory pathway historically used for nonpersonalized factor VIII products were followed for personalized hemophilia A therapies, then the previously untreated patient population would be the final one to gain access to the novel versions of the factor VIII product. This poses a dilemma in clinically evaluating whether factor VIII products designed with specific or modified sequences can decrease the incidence of inhibitors. Therefore, previously untreated patients appear to be the population that these personalized products would have to be tested in first. Current If the access and benefit-sharing protocol wasn't enough, those seeking to tap into a country's genetic resources must contend with rules for intellectual property (IP) on genetic resources, which for the past decade has been overseen by the World Intellectual Property Organization (WIPO; <http://www.wipo.int/tk/en/genetic/>). Although WIPO and CBD have attempted to harmonize oversight, as yet, there is no integration of WIPO IP rules and access and benefit sharing. What's more, several other instruments on genetic resources have proliferated over the past decade, including the Agreement on Trade-Related Aspects of Intellectual Property Rights (negotiated primarily by ministries of trade); the International Treaty on Plant Genetic Resources for Food and Agriculture (negotiated primarily by ministries of agriculture) and the Cartagena Protocol on Biosafety (negotiated primarily by ministries of science and technology). One should bear in mind that the CBD was negotiated under the aegis of the United Nations Environment Program, which brought together the ministries of the environment. All of this has resulted in a patchwork of regulatory requirements that must be navigated by those who wish to prospect for genetic resources, those who grant access to such genetic resources, and those whose duty is to implement the regulatory mechanisms to oversee the process.
Wanted: bioprospecting consultants
In this context, we feel there is an urgent need for reengagement of public and private sector participants in the processes on access and benefit sharing. In particular, we believe that consulting expertise is crucial to create trust and build skill sets between partners, with the aim of encouraging collaborations to implement access and benefit sharing in support of global R&D.
The idea of creating a facilitation or mediation mechanism to foster partnership and create trust among players in the bioprospecting process is not new. In 2002, Switzerland presented to the CBD the results of a feasibility study on the creation of a voluntary 3 "comprehensive, independent and neutral mediation service between the parties to the negotiation" that would "aim to ensure that the views and interests of all stakeholders are represented and that solutions, which meet the needs of all parties involved, are found. " At the time, this idea was dismissed because the stakeholders involved, including players in both the public and private sectors, feared that such by individuals, research institutions and companies. Such acts serve only to increase the tension between developed and developing nations and ultimately may threaten the foundations of open science.
The uncertainty also discourages industries-such as the pharmaceutical, biotech, seed and agriculture industriesthat rely on natural resources for the development of new products derived from collecting and investing in the development of products based on such resources. Those companies that aspire to do things the right way face challenges on several fronts: they often are confronted by allegations from third parties that they have misappropriated genetic resources (biopiracy); they may lack the relevant expertise and tools to navigate the complex legal territory of access and benefit sharing; they may have only minimal experience in practical skills, such as negotiation with local and international bodies; and they may face difficulties in identifying experts for professional advice.
Access and benefit-sharing regulations may also compromise public health efforts, such as acquisition of emerging infectious, human-disease pathogens for basic public health research. This was seen in efforts to rapidly obtain and transfer avian influenza strain H5N1 samples from infected patients at sites of outbreak (mainly in developing countries) to the global medical research communities (mainly in developed countries). Negotiations on access and benefit sharing took center stage instead of discussions about mechanisms to ensure prompt access to the samples in order to prevent the possible spread of a human pandemic.
As information associated with genetic resources also falls under the remit of access and benefit-sharing regulations, red tape associated with bioprospecting may also encumber genomics-type research. Restrictions on access and burdensome requirements for benefit sharing also serve to hinder industrial pursuit of natural targets that may provide starting points for medical products against public health needs.
Lastly, academia-perhaps the least equipped stakeholder for navigating the access and benefit-sharing framework-is also likely to be negatively affected by the language in the current protocol. Noncommercial uses of genetic resources are subject to access and benefit-sharing regulations; indeed, many countries do not make the distinction between noncommercial and commercial uses 2 , even though simplified procedures have been and institutional mechanisms to promote compliance with the Protocol and address cases of noncompliance.
The fact is, however, that the somewhat ambiguous language of the Nagoya Protocol presents several hurdles to any company or individual seeking to legitimately collect and invest in the development of products based on natural resources. Together with the proliferation of overlapping treaties and agreements and the involvement of an increasingly complex patchwork of international agencies, bioprospecting now represents a daunting legal challenge for any entity seeking to access the genetic resources of a particular country. For these reasons, we believe there is an urgent need for consultants to facilitate partnerships and foster trust among players in the bioprospecting process.
Last year's Nagoya Protocol found an historic consensus on four key issues in access and benefit sharing: first, the extent to which past access in a particular territory can affect benefit sharing (Preamble and Article 3); second, the extent to which commercial and noncommercial uses of genetic resources translate to fair and equitable benefit sharing over the diversity of genetic resources (Articles 5 and 8); third, how derivatives of genetic resources can be defined and the extent to which those derivatives are included under the access and benefit-sharing framework and that framework is put into practice (Articles 2 and 6); and fourth, the mechanisms by which individual countries not only provide authorization on access and benefit sharing through specific national agencies (Article 13) but also set up checkpoints to monitor trafficking of genetic resources in compliance with domestic legislation and regulatory requirements (Articles 15 and 17).
For this consensus to be achieved, however, rather ambiguous wording needed to be introduced into the protocol. For instance, it is unclear whether Article 17, which relates to the monitoring of formal trafficking of genetic resources, calls for compulsory establishment of a regulatory system or more arbitrary responses by competent authorities within the nation in question. It seems that many nations providing genetic resources could be uncertain about sharing their resources with recipient countries without a better defined arrangement. We believe this ambiguity will be detrimental to both users and providers of genetic resources in the long term.
One reason the ambiguity is harmful is that it provides an opportunity for freeriding and encourages unlawful behavior ensure an entity remains in compliance with terms of access and future benefit sharing as well as monitor and intervene in the initial deal of the material transfer 1, 6 . It will be interesting to see if this suggestion will receive support by the market through creative entrepreneurs interested in the area of bioprospecting consulting.
this would ensure that participants build capacity and receive advice in a relationship of trust and confidence. To provide such a service, the consultancy would need to be equipped with the necessary legal, scientific, technological and marketing skills to improve the capacity of its 'clients' in a way that encourages rather than detracts from engaging in the activity of bioprospecting.
Personnel trained in law (particularly IP rights and biodiversity laws), biological sciences and business development would be important to ensure that such businesses establish their professional credibility in the market. It would also be essential that these services have an understanding and appreciation of the various users and providers, and the needs of different industries, so that the advice provided is pragmatic and useful. Specialists would also be needed with expertise in specific regions, such as Japan 4 and Himalayan countries 5 .
In the area of bioprospecting, it is extremely important to act, as well as to be seen, as fair negotiators. The type of consulting business we propose would be unique in that it could serve as a means to build capacity and to create a potential link between public and private sectors for matters or negotiations related to access and benefit sharing. Such a consultant could a mediation process would incur further transaction costs and make bioprospecting less economically attractive.
We submit that the previous rejection of the mediation mechanism stems from the concern that a formal mediating body at the international level would further complicate matters; it is not an indication of a lack of interest in professional entities that would perform such a service. We also think that a market-led mediation mechanism is preferable to that originally proposed because the latter would likely be unable to serve as a truly independent and neutral body for parties who are attempting to negotiate for access by offering monetary and nonmonetary returns-two contrasting interests that would require bargaining and sophistication in negotiation skills. The nature of such negotiations is that it should be driven by parties who will be directly affected by the outcome of the deal-making, rather than by an outsider who may not be directly affected by the conclusion of such a process.
With this in mind, we propose that a better solution would be to encourage the creation of market-driven consulting services that provide professional advice to governments, companies, public research institutions, individual scientists and others, without conflict of interest;
